NCT02342314View on ClinicalTrials.gov

A Study of LY3143753 and LY3185643 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy
Interventions
DRUG

LY3143753 (Part A)

Administered via SC injection

DRUG

LY3185643 (Part B)

Administered via SC injection

DRUG

Placebo (Part A and Part B)

Administered via SC injection

DRUG

rGlucagon (Part B)

Administered via SC injection

Trial Locations (1)

LS2 9LH

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02342314 - A Study of LY3143753 and LY3185643 in Healthy Participants | Biotech Hunter | Biotech Hunter